General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...